between 2005 and the 30th of June 2010. We observed their administrative path. Among those available in the first teaching hospital group in France (42 hospitals), we evaluated the potential variables associated with the unit price growth rate before and after MA. RESULTS: During the study period, 77 ATUs obtained a MA, mostly after a European approval. Cancer represented the major therapeutic area with 21 drugs. After MA, 9 previous ATUs (12%) were not considered by the High commission for health (HAS) to have neither major nor important medical benefit and 19 (25%) were not supposed to bring some benefits compared to existing therapies. For the price growth rate's analysis, 57 drugs were retrieved (9 previous free ATUs were excluded): 68.4% had a decreasing price after MA whereas 17.5% increased and 14% were stable. Overall mean price growth rate was -12.1% Ϯ 22.6%. The improvement in medical benefit assessed by HAS was not a predictor of the growth rate (pϭ0.392). CONCLUSIONS: From these results, pharmaceutical companies seem marketing these compassionate drugs, for which the benefit/risk ratio is only presumed, at a price that guarantees a margin for future negotiations.
PHP11 FACT OR FALLACY: DOES MEDICAL TECHNOLOGY DRIVE HEALTH CARE SPENDING?
Sorenson C 1 , Drummond M 2 , Bhuiyan-Khan B 1 1 London School of Economics and Political Science, London, UK, 2 University of York, Heslington, York, UK OBJECTIVES: Health care spending has risen steadily in most countries, becoming a concern for decision-makers worldwide. Commentators often point to the diffusion of new medical technology as a key driver for burgeoning expenditures. This paper critically appraises this conjecture, based on an analysis of existing literature, with the aim of offering a more detailed and considered analysis of the impact of technological innovation on spending. METHODS: Key databases (e.g., PubMed, EMBASE) were searched to identify relevant literature. Several categories of studies (e.g., multivariate analyses, policy analyses) were included to cover different perspectives and issues regarding the relationship between medical technology and costs. Applicable abstracts were identified and selected articles reviewed. A standardised template was developed to extract relevant information from the select literature, which was then analysed for key themes across: impact of technology on costs, factors influencing this relationship, and noted methodological challenges in measuring such linkages. RESULTS: A total of 150 studies were reviewed. The analysis suggests that the relationship between medical technology and spending is complex and often conflicting. Study conclusions were often contingent on varying contextual factors, such as the sector examined, availability of other interventions, population trends, and the methodological approach employed. Moreover, the impact of medical technologies on costs differed across technologies; some (e.g., cancer drugs, invasive devices) had significant financial implications, while others were cost-neutral or cost-saving. Several studies examined technology in general, making it difficult to tease out the contribution of different types of interventions. CONCLUSIONS: Ascertaining the impact of technological advances on spending is difficult to quantify (and qualify). Issues of causality and incomplete knowledge of the interactions between technology and other factors affecting expenditures often constrain the reliability of analyses. We argue that it would be more productive to ask if investments in medical technology result in better value in health care.
PHP12 THEN AND NOW: THE EVOLUTION OF INTERNATIONAL REFERENCE PRICING GLOBALLY
Bharath A 1 , Ando G 2 1 IHS, London, London, UK, 2 IHS, London, UK OBJECTIVES: This study assesses the evolution of international reference pricing (IRP) across 34 countries, from 2006 to 2011. Its current influence on innovative drug pricing in the leading five European Union (EU) markets was also considered. METHODS: An international reference pricing matrix was created and reviewed to see if the basket of countries referred by nations to price their pharmaceuticals had changed. Pharmaceutical prices were also used to review 2011 prices of five randomly selected innovative blockbuster molecules across EU-5 countries; the molecules in question were bevacizumab, adalimumab, etanercept, rosuvastatin and infliximab. RESULTS: The EU-5 markets lead the reference basket used by countries in their price setting process both in 2006 and 2011. Countries that reference these markets are varied and not limited to economically similar markets both within and outside the EU. While there have been additions and deletions, many countries have largely maintained their reference basket of countries. Since 2006, more emerging markets have become IRP prescribers. Unlike Brazil, and Turkey, which followed IRP prior to 2006 and exclusively use developed country prices to price their own products, the newer emerging market followers have also chosen to include neighbouring countries and/or economically similar country prices in their mechanism. A comparison of 2011 prices across the EU-5 markets showed less price variation between countries that followed IRP compared to those that followed free pricing, but prices were not necessarily lower. CONCLUSIONS: Countries using IRP still rely on EU-5 drug prices to price their medicines. However, new adopters of the mechanism are including similar and neighbouring countries to arrive at affordable rates and prevent parallel export. With more emerging markets rolling out IRP, it is notable that in the absence of a set formula that identifies the lowest prices, this technique is one of cost harmonization rather than cost containment.
PHP13 A SURVEY OF PRICING TRENDS AROUND THE WORLD
Reinaud F 1 , Ando G 2 1 IHS, Paris, France, 2 IHS, London, UK OBJECTIVES: We surveyed pharmaceutical prices in 18 countries (mix of developed and emerging countries). The goal of the survey was to analyze and compare drug prices in an attempt to determine the countries where drug pricing procedures are more favorable or more stringent, as well as the countries where price cuts are common and where price increases can still be expected. METHODS: The methodology was based on estimated ex-manufacturer pricing data from PharmOnLine International, looking at current and historical drug prices in 18 countries. For each country, all prescription drugs by average manufacturer prices were looked at, as well as by therapeutic area. Several case studies were also analyzed. RESULTS: With countries having their own legislation and standards when it comes to drug pricing, significant price differentials are seen between countries. By far, conditions are still most favorable in the US. Legislation is more restrictive in other markets, notably in the European Union. Our data finds that the ongoing pricing reform in Germany has already had a significant impact on drug prices, which are dropping. Conditions are more attractive for innovative drugs in certain emerging countries -including Brazil or Russia -where pharmaceutical companies are increasingly investing as demonstrated with the large number of innovative drugs marketed in those countries. Additionally, a significant number of case studies demonstrate that innovative drugs are highly priced and that price increases can still be expected in those countries. CONCLUSIONS: With stringent pricing legislations in developed countries, opportunities are now seen in emerging countries where pharmaceutical companies increasingly invest. In these markets, the challenge is seen at the reimbursement and volume levels. Nevertheless, with governments enhancing their healthcare systems, the data points to the conclusion that the basket of drugs funded will increase in the near future.
PHP14 MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS
Wild L, Forster L Double Helix Consulting, London, UK OBJECTIVES: Indication expansion is a commonly utilized strategy to maximize return on investment for novel pharmaceuticals. As orphan drug designation can confer pricing, reimbursement and funding benefits, such indications can provide attractive targets for launch or follow-on indications. We aim to understand how expansions into or out of orphan indications affect a product's total pricing and reimbursement opportunity. METHODS: Centering our research on orphan indications, we explored three potential scenarios that could be reached when expanding a products indication (from highest to lowest frequency of occurrence): 1) Orphan (current) to Orphan (indication expansion); 2) Non-Orphan (current) to Orphan (indication expansion); and 30 Orphan (current) to Non-Orphan (indication expansion). We conducted analogue analysis across a variety of key global markets to understand the implications on pricing and reimbursement for a product moving between these groupings. RESULTS: The analogue analysis indication expansion between orphan indications is relatively common, particularly in oncology. Expansion in this way did not significantly impact product funding or access restrictions, although pricing can be affected by the increased patient population size. Further-A335 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
